PTC Therapeutics Inc (PTCT)

NASDAQ
30.79
-0.85(-2.69%)
After Hours
30.79
0.00(0.00%)
- Real-time Data
  • Volume:
    385,743
  • Day's Range:
    30.74 - 32.33
  • 52 wk Range:
    30.03 - 45.80

PTCT Overview

Prev. Close
31.64
Day's Range
30.74-32.33
Revenue
569.39M
Open
31.44
52 wk Range
30.03-45.8
EPS
-7.38
Volume
385,743
Market Cap
2.2B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
574,959
P/E Ratio
-
Beta
0.91
1-Year Change
-18.95%
Shares Outstanding
71,338,279
Next Earnings Date
Aug 09, 2022
What is your sentiment on PTC Therapeutics?
or
Market is currently closed. Voting is open during market hours.

PTC Therapeutics Inc News

PTC Therapeutics Inc Analysis

PTC Therapeutics Inc Company Profile

PTC Therapeutics Inc Company Profile

Employees
1172

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company’s splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • $PTCT Start accumulating if you haven't done so. 9/28 is fast approaching.. We may get documents days earlier. Don't get left behind
    0